Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
Stocks · News reference
Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx plans
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Argenx Will Discontinue Phase 3 UNITY Study Of Efgartigimod SC In Sjögren's Disease After IDMC Recommends Stopping For Futility At Interim Analysis; No New Safety Signals Identified
Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize